Clenbuterol

Active material: Clenbuterol
When ATH: R03CC13
CCF: Бронхолитический препарат – бета₂-adrenomimetik
When CSF: 12.01.01.02.01
Manufacturer: THANK TOTOK THAT AD (Bulgaria)

DOSAGE FORM, COMPOSITION AND PACKAGING

Syrup in the form of a transparent, colourless liquid with a characteristic smell of raspberries.

Excipients: sorbitol, glycerol, propylene glycol, sodium citrate dihydrate, lemon acid, metilparagidroksiʙenzoat, propilparagidroksibenzoat, butilparagidroksibenzoat, Sodium benzoate, Raspberry essence, Purified water.

100 мл – флаконы темного стекла (1) в комплекте с мерной ложкой – пачки картонные.

DESCRIPTION OF ACTIVE SUBSTANCES

Pharmacological action

Bronholitik, β is a stimulant₂-adrenoretseptorov prolonged action. Bronchodilatory effect due to the direct relaxing effect on the muscles of the bronchi. Can increase HEART RATE. He has also tokolitičeskim effect.

Pharmacokinetics

Provides a high degree of absorption. High concentrations up in the plasma through 15 minutes after a single reception and persist for 7-24 no. Report mostly kidneys. T_1/2 – 3 no.

Testimony

Prevention and relief of bronchospasm in bronchial asthma; bronchitis with BOS syndrome.

Dosage regimen

Taken orally at a dose of 2.5-20 mg 2 times / day. Dose set depending on patient age and clinical situation.

Side effect

Cardio-vascular system: tachycardia, arrythmia, low blood pressure.

CNS: jitter fingers, anxiety, headache.

From the digestive system: dry mouth, nausea.

Allergic reactions: the appearance of skin rash.

Other: kaliopenia.

Contraindications

Thyrotoxicosis, tachycardia, integuments, subaortalny stenoses rivers, acute phase of myocardial infarction, pregnancy, hypersensitivity to klenbuterolu.

Pregnancy and lactation

Contraindicated during pregnancy.

Cautions

Возможно развитие резистентности и синдрома “рикошета”.

We cannot allow the drug in the eye, especially in glaucoma.

Drug Interactions

Beta-adrenoblokatora are pharmacological antagonists of Clenbuterol and can resolve it.

Clenbuterol reduces effect gipoglikemicakih funds. Increases the risk of development of intracardiac conduction together with MAO inhibitors and theophylline. Increases toxicity of cardiac glycosides and increases the risk of arrhythmia. In combination with simpatomimeticakimi means going mutual increase toxicity.